Dominick Angiolillo, MD

Dr. Dominick J. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in Medicine and Cardiology. He subsequently pursued training in Interventional Cardiology at the Complutense University of Madrid in Spain. Ultimately, Dr. Angiolillo received his PhD in Cellular and Molecular Cardiology. After completing his training in the most prestigious academic centers in Europe, Dr. Angiolillo joined the University of Florida College of Medicine-Jacksonville in 2004. Currently, Dr. Angiolillo is a Professor of Medicine with Tenure status, Chief of Cardiology and Medical Director of the University of Florida Health Cardiovascular Center. He is also the Director of Cardiovascular Research, Program Director of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Dr. Angiolillo is board certified in Cardiovascular Disease and Interventional Cardiology by the American Board of Internal Medicine.

Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions. Amongst these he has received the 2013 Outstanding Achievement Award from the European Society of Cardiology and for 8 consecutive years (since 2014) he has been in the top 1 percent of most-cited researchers worldwide according to Clarivate Analytics (formerly Thomson Reuters’ list of The World’s Most Influential Scientific Minds). He has also been a key investigator in the clinical development of numerous novel antithrombotic agents, working along slide with drug regulating agencies in the United States (FDA) and Europe (EMA), towards approval of these drugs and product labeling updates. His success in obtaining extramural funding (>$25 million) has allowed to develop one of the most active clinical research centers in the United States as well as one of the leading centers for thrombosis research in the world.

Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as textbooks of cardiovascular medicine. He has authored over 600 peer-reviewed articles with nearly 60,000 citations, an H-index of 105, and iH-index of 447. He has authored nearly 40 book chapters, and he is the editor of his own textbook on antithrombotic medicine. Due to his major contributions to the field of antithrombotic therapy in patients with cardiovascular disease manifestations, Dr. Angiolillo has been invited to deliver numerous lectures across the globe. His international visibility has also allowed him to develop a very active research program attracting physicians and scientists from across the globe to train under his leadership. In addition, to these responsibilities, Dr. Angiolillo has been a clinical mentor to numerous residents and fellows for which he has been recognized in multiple occasions with an Exemplary Teacher Award. His leadership role as an academic clinician scientist has allowed to him to nurture and promote career growth and development of many young trainees pursuing both academic and clinical careers in the United States and abroad.

Dr. Angiolillo is an active member of many cardiovascular societies in the Unites States and Europe. In addition, he is on the editorial board of numerous cardiovascular journals, some of which he also holds leadership roles. He is a scientific reviewer for many major journals and extramural funding agencies, including the National Institute of Health, and other federal funding agencies in several European countries. He is also Chair of the American Board of Internal Medicine examination writing committee in Interventional Cardiology.


Baim- and Baim-affiliated faculty members disclose the conflicts of interest for the Baim Institute which can be viewed here.